Your trusted source for investing success

Tag: liver

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Albireo to Receive More than $55 Million in Nondilutive Cash Payments

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Japan’s Ministry of Health, Labor and Welfare has approved the new drug application for elobixibat for the treatment of chronic constipation in Japan.

As quoted in the press release:
“The approval of elobixibat in Japan marks the

Celsion Corporation Provides Corporate Update and 2018 Outlook

Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a year-end 2017 corporate review and announced clinical progress for two of its development programs: ThermoDox®, a proprietary, heat-activated liposomal encapsulation of doxorubicin, which is in Phase III development for treatment of primary liver cancer; and GEN-1, an IL-12 DNA plasmid

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Albireo to Receive More than Million in Nondilutive Cash Payments

URL: https://investingnews.com/daily/life-science-investing/biotech-investing/albireo-receive-55-million-nondilutive-cash-payments/